Back to search results

Targeted Radiation for Metastatic Non-Small Cell Lung Cancer

This study is looking at whether adding L-SABR (a type of targeted radiation therapy) to standard drug therapy is better than standard drug therapy alone for people with metastatic non-small cell lung cancer (NSCLC). Standard drug therapy includes anti-PD-(L)1 based immunotherapy, which may also include platinum-based chemotherapy. You might be able to join if you are over 18, have stage IV NSCLC, and do not have certain mutations in EGFR, BRAF, ALK, or ROS-1. The researchers will measure how long people live without their cancer getting worse, for up to 4 years. The study plans to enroll 68 participants, but its current status is unclear.

Study design
This interventional study plans to enroll 68 participants. It is comparing L-SABR plus standard drug therapy to standard drug therapy alone.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for up to 4 years to measure how long they live without their cancer getting worse.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05657873

A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)

Recruiting
PHASE2Ages 18+InterventionalTreatment
Memorial Sloan Kettering Cancer Center
~68 participants
Updated 2026-05-07 on ClinicalTrials.gov
What's tested:L-SABRAnti-PD-(L)1 based immunotherapyPlatinum based chemotherapy

At a glance

Recruiting sites
9 of 9 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Median progression-free survival
Measured over up to 4 years

Conditions

Non Small Cell Lung Cancer
Non Small Cell Lung Cancer Metastatic
Non-small Cell Carcinoma
NSCLC
NSCLC Stage IV

Explore related trials

Lung Non-Small Cell Carcinoma

Where it's being run

9 sites across 4 states
New York4
New Jersey3
Florida1
Pennsylvania1

Study leadership

  • Paul Romesser, MD · PRINCIPAL_INVESTIGATOR · Memorial Sloan Kettering Cancer Center

Who to contact

Paul Romesser, MD
[email protected]
646-888-2118
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Be greater than 18 years of age on day of signing informed consent.
Have a histologically confirmed diagnosis of stage IV NSCLC (includes patients who have progressed on durvalumab for Stage III NSCLC) without known mutations in (EGFR) or BRAF or rearrangements in ALK (anaplastic lymphoma kinase) or ROS-1.
Newly diagnosed metastatic non-small cell lung cancer (NSCLC), including both de novo and secondary metastatic disease, with one or more liver metastases
Plan to initiate standard of care anti-PD-(L)1 based immunotherapy +/- platinum based chemotherapy for at least 3 cycles
Have a performance status of 0-2 on the ECOG Performance Scale.
Liver function tests:
Total Bilirubin ≤ 1.5 x ULN
AST/ ALT ≤ 5 x ULN
Eligible for L- SABR to all liver metastases as determined by the treating radiation oncologist
Patients with known HIV are eligible provided they are under treatment with effective anti-retroviral therapy with CD4 count \>200 cells/microliter within 28 days prior to registration

Exclusion

Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen should be included.
Patients with prior external beam radiation therapy to the liver.
Patients with known active Hepatitis B or Hepatitis C.
Patients with immunosuppression including pharmacological immunosuppression with chronic steroids or immune modulators like cyclosporin or methotrexate and patients with active autoimmune disease.
Patients who are pregnant or breastfeeding
Men or women not using effective contraception.

What this trial measures

  • Median progression-free survivalup to 4 years

    Primary outcomes is to determine if L-SABR, when added to first line standard of care anti-PD-(L)1 based immunotherapy +/- chemotherapy, can improve median progression-free survival (PFS) in patients with metastatic NSCLC involving the liver.